Clinical trial · people

Setmelanotide: 80% (POMC) and 45% (LEPR) lost at least 10% weight

Checked against the paper Clinical trialPublished by PepVault

The takeaway

This paper shows setmelanotide's effect in two rare genetic causes of obesity, not in common obesity.

Kind
Clinical trial
Studied in
People
Published
2020
Journal
Lancet Diabetes Endocrinol

What they tested

The teams tested whether setmelanotide reduces weight and hunger in people with severe obesity caused by POMC or LEPR deficiency, rare inherited gene changes in the body's weight-control pathway.

How the study was done

Two single-arm, open-label phase 3 trials (everyone got the drug and knew it) at 10 hospitals enrolled people aged 6 or older: 10 in the POMC trial and 11 in the LEPR trial. After 12 weeks on the drug, those who lost at least 5 kg (or 5% if they weighed under 100 kg) entered an 8-week blinded phase with 4 weeks each of drug and placebo (a dummy shot), then 32 more weeks on the drug.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking setmelanotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At about 1 year, 80% of POMC participants and 45% of LEPR participants had lost at least 10% of their starting weight. In participants aged 12 or older who passed the early weight-loss cutoff, the worst-hunger score fell by 27.1% in the POMC trial (7 people) and 43.7% in the LEPR trial (7 people). Injection site reactions happened in everyone, hyperpigmentation (skin darkening) in all POMC participants, and nausea and vomiting were also seen. There were no serious treatment-related side effects in either trial.

What it doesn’t show

Both trials were very small, open-label and had no comparison group for the main 1-year result, and hunger was measured only in people who responded early. The trials were funded by Rhythm Pharmaceuticals.

The paper

Clément et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020.

The compound

More studies on Setmelanotide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking setmelanotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo